Cognitive and Memory Enhancer Drugs Market
Cognitive enhancers are drugs and supplements, which are majorly used by patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. In addition, these drugs are used by health individuals to improve cognitive functions such as memory, intelligence, motivation, stamina, alertness attention, and concentration.
The global cognitive and memory enhancer drugs market was valued at $3,680 million in 2016, and is projected to reach $6,598 million by 2023, growing at a CAGR of 8.6% from 2017 to 2023. The growth of the global cognitive and memory enhancer drugs market is driven by surge in geriatric population and rise in prevalence of neurological & memory-related disorders. Furthermore, the benefits offered by cognitive drugs such as improved memory and reasoning fuel the market growth. However, ethical issues related to the use of these drugs impede the market growth.
The global cognitive and memory enhancer drugs market is segmented on the basis of product, application, and region. Based on product, the market is categorized into Aricept, Razadyne, Namenda, Exelon, Provigil, Ritalin, Adderall, and others. The applications covered in the study include disease treatment, academic performance, athletic performance, and others. Disease treatment segment is further bifurcated into developmental conditions and neurodegenerative disease. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
By Product
The global cognitive and memory enhancer drugs market was valued at $3,680 million in 2016, and is projected to reach $6,598 million by 2023, growing at a CAGR of 8.6% from 2017 to 2023. The growth of the global cognitive and memory enhancer drugs market is driven by surge in geriatric population and rise in prevalence of neurological & memory-related disorders. Furthermore, the benefits offered by cognitive drugs such as improved memory and reasoning fuel the market growth. However, ethical issues related to the use of these drugs impede the market growth.
The global cognitive and memory enhancer drugs market is segmented on the basis of product, application, and region. Based on product, the market is categorized into Aricept, Razadyne, Namenda, Exelon, Provigil, Ritalin, Adderall, and others. The applications covered in the study include disease treatment, academic performance, athletic performance, and others. Disease treatment segment is further bifurcated into developmental conditions and neurodegenerative disease. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides an extensive analysis of the current and emerging trends and dynamics in the global cognitive and memory enhancer drugs market.
- This study provides the competitive landscape of the global market to predict the competitive environment across geographies.
- This report entails the detailed quantitative analysis of the current trends and future estimations to identify the prevailing opportunities.
- Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
- Region- and country-wise analysis is provided to understand the market trends and dynamics.
By Product
- Aricept
- Exelon
- Namenda
- Razadyne
- Provigil
- Ritalin
- Adderall
- Others
- Disease TreatmentDevelopmental Conditions
- Neurodegenerative Conditions
- Academic Performance
- Athletic Performance
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Pfizer Inc.
- Eisai Co., Ltd.
- Allergan, Inc.
- Novartis AG
- Shire
- Johnson & Johnson
- Takeda Pharmaceutical Company Limited
- AlternaScript LLC
- Cephalon, Inc. (Teva Pharmaceutical Industries Ltd.)
- Ceretropic
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top winning strategies
3.2.1.1. Top winning strategies, by year, 2015-2018
3.2.1.2. Top winning strategies, by development, 2015-2018 (%)
3.2.1.3. Top winning strategies, by company, 2015-2018
3.2.2. Top investment pockets
3.3. Market share analysis, 2016
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rapidly aging population
3.4.1.2. High incidence of neurodegenerative disorders
3.4.1.3. Benefits of smart drugs
3.4.2. Restraints
3.4.2.1. Ethical issues
3.4.3. Opportunities
3.4.3.1. Effective strength of the drugs
CHAPTER 4: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Aricept
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Exelon
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Namenda
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Razadyne
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Provigil
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Ritalin
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.8. Adderall
4.8.1. Key market trends, growth factors and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country
4.9. Others
4.9.1. Key market trends, growth factors and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country
CHAPTER 5: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Disease treatment
5.2.1. Market size and forecast by type
5.2.2. Developmental conditions
5.2.2.1. Market size and forecast
5.2.3. Neurodegenerative disorders
5.2.3.1. Market size and forecast
5.2.4. Market size and forecast, by region
5.2.5. Market analysis, by country
5.3. Academic performance
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Athletic performance
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Others
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
CHAPTER 6: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S. cognitive and memory enhancer drugs market
6.2.2.1.1. U.S. market size and forecast, by product
6.2.2.1.2. U.S. market size and forecast, by application
6.2.2.2. Canada cognitive and memory enhancer drugs market
6.2.2.2.1. Canada market size and forecast, by product
6.2.2.2.2. Canada market size and forecast, by application
6.2.2.3. Mexico cognitive and memory enhancer drugs market
6.2.2.3.1. Mexico market size and forecast, by product
6.2.2.3.2. Mexico market size and forecast, by application
6.2.3. North America market size and forecast, by product
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany cognitive and memory enhancer drugs market
6.3.2.1.1. Germany market size and forecast, by product
6.3.2.1.2. Germany market size and forecast, by application
6.3.2.2. France cognitive and memory enhancer drugs market
6.3.2.2.1. France market size and forecast, by product
6.3.2.2.2. France market size and forecast, by application
6.3.2.3. UK cognitive and memory enhancer drugs market
6.3.2.3.1. UK market size and forecast, by product
6.3.2.3.2. UK market size and forecast, by application
6.3.2.4. Italy cognitive and memory enhancer drugs market
6.3.2.4.1. Italy market size and forecast, by product
6.3.2.4.2. Italy market size and forecast, by application
6.3.2.5. Spain cognitive and memory enhancer drugs market
6.3.2.5.1. Spain market size and forecast, by product
6.3.2.5.2. Spain market size and forecast, by application
6.3.2.6. Rest of Europe cognitive and memory enhancer drugs market
6.3.2.6.1. Rest of Europe market size and forecast, by product
6.3.2.6.2. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by product
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan cognitive and memory enhancer drugs market
6.4.2.1.1. Japan market size and forecast, by product
6.4.2.1.2. Japan market size and forecast, by application
6.4.2.2. China cognitive and memory enhancer drugs market
6.4.2.2.1. China market size and forecast, by product
6.4.2.2.2. China market size and forecast, by application
6.4.2.3. India cognitive and memory enhancer drugs market
6.4.2.3.1. India market size and forecast, by product
6.4.2.3.2. India market size and forecast, by application
6.4.2.4. Australia cognitive and memory enhancer drugs market
6.4.2.4.1. Australia market size and forecast, by product
6.4.2.4.2. Australia market size and forecast, by application
6.4.2.5. Rest of Asia-Pacific cognitive and memory enhancer drugs market
6.4.2.5.1. Rest of Asia-Pacific market size and forecast, by product
6.4.2.5.2. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by product
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast by country
6.5.2.1. Brazil cognitive and memory enhancer drugs market
6.5.2.1.1. Brazil market size and forecast, by product
6.5.2.1.2. Brazil market size and forecast, by application
6.5.2.2. Saudi Arabia cognitive and memory enhancer drugs market
6.5.2.2.1. Saudi Arabia market size and forecast, by product
6.5.2.2.2. Saudi Arabia market size and forecast, by application
6.5.2.3. South Africa cognitive and memory enhancer drugs market
6.5.2.3.1. South Africa market size and forecast, by product
6.5.2.3.2. South Africa market size and forecast, by application
6.5.2.4. Rest of LAMEA cognitive and memory enhancer drugs market
6.5.2.4.1. Rest of LAMEA market size and forecast, by product
6.5.2.4.2. Rest of LAMEA market size and forecast, by application
6.5.3. LAMEA market size and forecast, by product
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. Allergan Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. AlternaScript LLC
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.3. Ceretropic
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product portfolio
7.4. Eisai Co. Ltd.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Johnson & Johnson
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. Novartis International AG
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Pfizer Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Shire Plc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Takeda Pharmaceutical Company Ltd.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
1.1. Report description
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top winning strategies
3.2.1.1. Top winning strategies, by year, 2015-2018
3.2.1.2. Top winning strategies, by development, 2015-2018 (%)
3.2.1.3. Top winning strategies, by company, 2015-2018
3.2.2. Top investment pockets
3.3. Market share analysis, 2016
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rapidly aging population
3.4.1.2. High incidence of neurodegenerative disorders
3.4.1.3. Benefits of smart drugs
3.4.2. Restraints
3.4.2.1. Ethical issues
3.4.3. Opportunities
3.4.3.1. Effective strength of the drugs
CHAPTER 4: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Aricept
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Exelon
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Namenda
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Razadyne
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Provigil
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Ritalin
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.8. Adderall
4.8.1. Key market trends, growth factors and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country
4.9. Others
4.9.1. Key market trends, growth factors and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country
CHAPTER 5: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Disease treatment
5.2.1. Market size and forecast by type
5.2.2. Developmental conditions
5.2.2.1. Market size and forecast
5.2.3. Neurodegenerative disorders
5.2.3.1. Market size and forecast
5.2.4. Market size and forecast, by region
5.2.5. Market analysis, by country
5.3. Academic performance
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Athletic performance
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Others
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
CHAPTER 6: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S. cognitive and memory enhancer drugs market
6.2.2.1.1. U.S. market size and forecast, by product
6.2.2.1.2. U.S. market size and forecast, by application
6.2.2.2. Canada cognitive and memory enhancer drugs market
6.2.2.2.1. Canada market size and forecast, by product
6.2.2.2.2. Canada market size and forecast, by application
6.2.2.3. Mexico cognitive and memory enhancer drugs market
6.2.2.3.1. Mexico market size and forecast, by product
6.2.2.3.2. Mexico market size and forecast, by application
6.2.3. North America market size and forecast, by product
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany cognitive and memory enhancer drugs market
6.3.2.1.1. Germany market size and forecast, by product
6.3.2.1.2. Germany market size and forecast, by application
6.3.2.2. France cognitive and memory enhancer drugs market
6.3.2.2.1. France market size and forecast, by product
6.3.2.2.2. France market size and forecast, by application
6.3.2.3. UK cognitive and memory enhancer drugs market
6.3.2.3.1. UK market size and forecast, by product
6.3.2.3.2. UK market size and forecast, by application
6.3.2.4. Italy cognitive and memory enhancer drugs market
6.3.2.4.1. Italy market size and forecast, by product
6.3.2.4.2. Italy market size and forecast, by application
6.3.2.5. Spain cognitive and memory enhancer drugs market
6.3.2.5.1. Spain market size and forecast, by product
6.3.2.5.2. Spain market size and forecast, by application
6.3.2.6. Rest of Europe cognitive and memory enhancer drugs market
6.3.2.6.1. Rest of Europe market size and forecast, by product
6.3.2.6.2. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by product
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan cognitive and memory enhancer drugs market
6.4.2.1.1. Japan market size and forecast, by product
6.4.2.1.2. Japan market size and forecast, by application
6.4.2.2. China cognitive and memory enhancer drugs market
6.4.2.2.1. China market size and forecast, by product
6.4.2.2.2. China market size and forecast, by application
6.4.2.3. India cognitive and memory enhancer drugs market
6.4.2.3.1. India market size and forecast, by product
6.4.2.3.2. India market size and forecast, by application
6.4.2.4. Australia cognitive and memory enhancer drugs market
6.4.2.4.1. Australia market size and forecast, by product
6.4.2.4.2. Australia market size and forecast, by application
6.4.2.5. Rest of Asia-Pacific cognitive and memory enhancer drugs market
6.4.2.5.1. Rest of Asia-Pacific market size and forecast, by product
6.4.2.5.2. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by product
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast by country
6.5.2.1. Brazil cognitive and memory enhancer drugs market
6.5.2.1.1. Brazil market size and forecast, by product
6.5.2.1.2. Brazil market size and forecast, by application
6.5.2.2. Saudi Arabia cognitive and memory enhancer drugs market
6.5.2.2.1. Saudi Arabia market size and forecast, by product
6.5.2.2.2. Saudi Arabia market size and forecast, by application
6.5.2.3. South Africa cognitive and memory enhancer drugs market
6.5.2.3.1. South Africa market size and forecast, by product
6.5.2.3.2. South Africa market size and forecast, by application
6.5.2.4. Rest of LAMEA cognitive and memory enhancer drugs market
6.5.2.4.1. Rest of LAMEA market size and forecast, by product
6.5.2.4.2. Rest of LAMEA market size and forecast, by application
6.5.3. LAMEA market size and forecast, by product
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. Allergan Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. AlternaScript LLC
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.3. Ceretropic
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product portfolio
7.4. Eisai Co. Ltd.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Johnson & Johnson
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. Novartis International AG
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Pfizer Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Shire Plc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Takeda Pharmaceutical Company Ltd.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
LIST OF TABLES
TABLE 01. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 02. ARICEPT MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 03. EXELON MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 04. NAMENDA MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 05. RAZADYNE MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 06. PROVIGIL MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 07. RITALIN MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 08. ADDERALL MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 09. OTHERS MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 11. EFFECT OF THE COGNITIVE AND MEMORY ENHANCER DRUGS USED FOR DISEASE TREATMENT
TABLE 12. DISEASE TREATMENT MARKET REVENUE, BY TYPE, 2016-2023 ($MILLION)
TABLE 13. DISEASE TREATMENT MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 14. ACADEMIC PERFORMANCE MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 15. ATHLETIC PERFORMANCE MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 16. OTHER APPLICATIONS MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 17. COGNITIVE AND MEMEORY ENHANCER DRUGS MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 18. NORTH AMERICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19. U.S. COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 20. U.S. COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 21. CANADA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 22. CANADA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 23. MEXICO COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 24. MEXICO COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 25. MEXICO COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 26. NORTH AMERICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 27. PEOPLE SUFFERING FROM DEMENTIA IN GERMANY, 2013
TABLE 28. EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 29. GERMANY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 30. GERMANY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 31. FRANCE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 32. FRANCE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 33. UK COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 34. UK COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 35. ITALY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 36. ITALY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 37. SPAIN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 38. SPAIN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 39. REST OF EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 40. REST OF EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 41. EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 42. EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 43. ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 44. JAPAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 45. JAPAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46. CHINA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 47. CHINA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 48. INDIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 49. INDIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 50. AUSTRALIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 51. AUSTRALIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 52. REST OF ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 53. REST OF ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 54. ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 55. ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 56. LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 57. BRAZIL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 58. BRAZIL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 59. SAUDI ARABIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 60. SAUDI ARABIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 61. SOUTH AFRICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 62. SOUTH AFRICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 63. REST OF LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 64. REST OF LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 65. LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 66. LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 67. ALLERGAN: COMPANY SNAPSHOT
TABLE 68. ALLERGAN: OPERATING SEGMENTS
TABLE 69. ALLERGAN: PRODUCT PORTFOLIO
TABLE 70. ALTERNASCRIPT: COMPANY SNAPSHOT
TABLE 71. ALTERNASCRIPT: OPERATING SEGMENTS
TABLE 72. ALTERNASCRIPT: PRODUCT PORTFOLIO
TABLE 73. CERETROPIC: COMPANY SNAPSHOT
TABLE 74. CERETROPIC: PRODUCT PORTFOLIO
TABLE 75. EISAI: COMPANY SNAPSHOT
TABLE 76. EISAI: OPERATING SEGMENTS
TABLE 77. EISAI: PRODUCT PORTFOLIO
TABLE 78. J&J: COMPANY SNAPSHOT
TABLE 79. J&J: OPERATING SEGMENTS
TABLE 80. J&J: PRODUCT PORTFOLIO
TABLE 81. NOVARTIS: COMPANY SNAPSHOT
TABLE 82. NOVARTIS: OPERATING SEGMENTS
TABLE 83. NOVARTIS: PRODUCT PORTFOLIO
TABLE 84. PFIZER: COMPANY SNAPSHOT
TABLE 85. PFIZER: OPERATING SEGMENTS
TABLE 86. PFIZER: PRODUCT PORTFOLIO
TABLE 87. SHIRE: COMPANY SNAPSHOT
TABLE 88. SHIRE: PRODUCT PORTFOLIO
TABLE 89. TAKEDA: COMPANY SNAPSHOT
TABLE 90. TAKEDA: OPERATING SEGMENTS
TABLE 91. TAKEDA: PRODUCT PORTFOLIO
TABLE 92. TEVA: COMPANY SNAPSHOT
TABLE 93. TEVA: OPERATING SEGMENTS
TABLE 94. TEVA: PRODUCT PORTFOLIO
TABLE 01. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 02. ARICEPT MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 03. EXELON MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 04. NAMENDA MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 05. RAZADYNE MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 06. PROVIGIL MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 07. RITALIN MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 08. ADDERALL MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 09. OTHERS MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 11. EFFECT OF THE COGNITIVE AND MEMORY ENHANCER DRUGS USED FOR DISEASE TREATMENT
TABLE 12. DISEASE TREATMENT MARKET REVENUE, BY TYPE, 2016-2023 ($MILLION)
TABLE 13. DISEASE TREATMENT MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 14. ACADEMIC PERFORMANCE MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 15. ATHLETIC PERFORMANCE MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 16. OTHER APPLICATIONS MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 17. COGNITIVE AND MEMEORY ENHANCER DRUGS MARKET REVENUE, BY REGION, 2016-2023 ($MILLION)
TABLE 18. NORTH AMERICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19. U.S. COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 20. U.S. COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 21. CANADA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 22. CANADA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 23. MEXICO COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 24. MEXICO COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 25. MEXICO COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 26. NORTH AMERICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 27. PEOPLE SUFFERING FROM DEMENTIA IN GERMANY, 2013
TABLE 28. EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 29. GERMANY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 30. GERMANY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 31. FRANCE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 32. FRANCE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 33. UK COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 34. UK COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 35. ITALY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 36. ITALY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 37. SPAIN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 38. SPAIN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 39. REST OF EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 40. REST OF EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 41. EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 42. EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 43. ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 44. JAPAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 45. JAPAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46. CHINA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 47. CHINA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 48. INDIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 49. INDIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 50. AUSTRALIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 51. AUSTRALIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 52. REST OF ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 53. REST OF ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 54. ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 55. ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 56. LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 57. BRAZIL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 58. BRAZIL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 59. SAUDI ARABIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 60. SAUDI ARABIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 61. SOUTH AFRICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 62. SOUTH AFRICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 63. REST OF LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 64. REST OF LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 65. LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 66. LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET REVENUE, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 67. ALLERGAN: COMPANY SNAPSHOT
TABLE 68. ALLERGAN: OPERATING SEGMENTS
TABLE 69. ALLERGAN: PRODUCT PORTFOLIO
TABLE 70. ALTERNASCRIPT: COMPANY SNAPSHOT
TABLE 71. ALTERNASCRIPT: OPERATING SEGMENTS
TABLE 72. ALTERNASCRIPT: PRODUCT PORTFOLIO
TABLE 73. CERETROPIC: COMPANY SNAPSHOT
TABLE 74. CERETROPIC: PRODUCT PORTFOLIO
TABLE 75. EISAI: COMPANY SNAPSHOT
TABLE 76. EISAI: OPERATING SEGMENTS
TABLE 77. EISAI: PRODUCT PORTFOLIO
TABLE 78. J&J: COMPANY SNAPSHOT
TABLE 79. J&J: OPERATING SEGMENTS
TABLE 80. J&J: PRODUCT PORTFOLIO
TABLE 81. NOVARTIS: COMPANY SNAPSHOT
TABLE 82. NOVARTIS: OPERATING SEGMENTS
TABLE 83. NOVARTIS: PRODUCT PORTFOLIO
TABLE 84. PFIZER: COMPANY SNAPSHOT
TABLE 85. PFIZER: OPERATING SEGMENTS
TABLE 86. PFIZER: PRODUCT PORTFOLIO
TABLE 87. SHIRE: COMPANY SNAPSHOT
TABLE 88. SHIRE: PRODUCT PORTFOLIO
TABLE 89. TAKEDA: COMPANY SNAPSHOT
TABLE 90. TAKEDA: OPERATING SEGMENTS
TABLE 91. TAKEDA: PRODUCT PORTFOLIO
TABLE 92. TEVA: COMPANY SNAPSHOT
TABLE 93. TEVA: OPERATING SEGMENTS
TABLE 94. TEVA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MARKET SHARE ANALYSIS, 2016
FIGURE 04. COMPARATIVE ANALYSIS OF ARICEPT MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 05. COMPARATIVE ANALYSIS OF EXELON MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 06. COMPARATIVE ANALYSIS OF NAMENDA MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 07. COMPARATIVE ANALYSIS OF RAZADYNE MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 08. COMPARATIVE ANALYSIS OF PROVIGIL MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 09. COMPARATIVE ANALYSIS OF RITALIN MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 10. COMPARATIVE ANALYSIS OF ADDERALL MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 11. COMPARATIVE ANALYSIS OF OTHER DRUGS MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 12. DEVELOPMENTAL CONDITIONS MARKET, 2016-2023 ($MILLION)
FIGURE 13. NEURODEGENERATIVE DISORDERS MARKET, 2016-2023 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF DISEASE TREATMENT MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF ACADEMIC PERFORMANCE MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF ATHLETIC PERFORMANCE MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 17. COMPARATIVE ANALYSIS OF OTHER APPLICATIONS MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 18. POPULATION STRUCTURE BY MAJOR AGE GROUPS, EU-28
FIGURE 19. ALLERGAN: NET SALES, 2014-2016 ($MILLION)
FIGURE 20. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 21. EISAI: NET SALES, 2014-2016 ($MILLION)
FIGURE 22. EISAI: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 23. J&J: NET SALES, 2014-2016 ($MILLION)
FIGURE 24. J&J: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 25. J&J: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 26. NOVARTIS: NET SALES, 2015-2017 ($MILLION)
FIGURE 27. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 28. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 29. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 30. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 31. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 32. SHIRE: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. SHIRE: REVENUE SHARE BY PRODUCT, 2016 (%)
FIGURE 34. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 35. TAKEDA: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. TAKEDA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 37. TAKEDA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 38. TEVA: NET SALES, 2014-2016 ($MILLION)
FIGURE 39. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 40. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 01. MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MARKET SHARE ANALYSIS, 2016
FIGURE 04. COMPARATIVE ANALYSIS OF ARICEPT MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 05. COMPARATIVE ANALYSIS OF EXELON MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 06. COMPARATIVE ANALYSIS OF NAMENDA MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 07. COMPARATIVE ANALYSIS OF RAZADYNE MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 08. COMPARATIVE ANALYSIS OF PROVIGIL MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 09. COMPARATIVE ANALYSIS OF RITALIN MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 10. COMPARATIVE ANALYSIS OF ADDERALL MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 11. COMPARATIVE ANALYSIS OF OTHER DRUGS MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 12. DEVELOPMENTAL CONDITIONS MARKET, 2016-2023 ($MILLION)
FIGURE 13. NEURODEGENERATIVE DISORDERS MARKET, 2016-2023 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF DISEASE TREATMENT MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF ACADEMIC PERFORMANCE MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF ATHLETIC PERFORMANCE MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 17. COMPARATIVE ANALYSIS OF OTHER APPLICATIONS MARKET REVENUE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 18. POPULATION STRUCTURE BY MAJOR AGE GROUPS, EU-28
FIGURE 19. ALLERGAN: NET SALES, 2014-2016 ($MILLION)
FIGURE 20. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 21. EISAI: NET SALES, 2014-2016 ($MILLION)
FIGURE 22. EISAI: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 23. J&J: NET SALES, 2014-2016 ($MILLION)
FIGURE 24. J&J: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 25. J&J: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 26. NOVARTIS: NET SALES, 2015-2017 ($MILLION)
FIGURE 27. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 28. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 29. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 30. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 31. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 32. SHIRE: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. SHIRE: REVENUE SHARE BY PRODUCT, 2016 (%)
FIGURE 34. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 35. TAKEDA: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. TAKEDA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 37. TAKEDA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 38. TEVA: NET SALES, 2014-2016 ($MILLION)
FIGURE 39. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 40. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
